Vaxcyte (PCVX) Corporate presentation summary

Mission and platform overview

• Focused on engineering high-fidelity vaccines to protect against bacterial diseases globally.

• Utilizes a proprietary cell-free protein synthesis platform (XpressCF) enabling rapid, flexible, and scalable vaccine candidate development.

• Platform allows site-specific conjugation, producing broader-spectrum vaccines and novel protein antigens beyond conventional methods.

Pneumococcal conjugate vaccine (PCV) franchise

• VAX-31 is the broadest-spectrum PCV in clinical development, designed to cover ~95% of invasive pneumococcal disease (IPD) in U.S. adults ≥50 years.

• VAX-24 and VAX-31 target both adult and pediatric populations, with VAX-31 also aiming for ~92% IPD coverage in children.

• Carrier-sparing, site-specific conjugation technology minimizes immune suppression and enables addition of more serotypes.

• Phase 3 OPUS program for VAX-31 in adults is fully enrolled, with topline data expected in Q4 2026.

• Positive Phase 1/2 data for VAX-31 showed robust immune responses and safety comparable to PCV20.

Market opportunity and adoption drivers

• Global pneumococcal vaccine market is ~$8B, expected to grow to ~$12B by 2030, driven by expanded adult recommendations.

• Broader serotype and disease coverage is the primary adoption driver, with rapid uptake seen for higher-valency PCVs.

• VAX-31 and VAX-24 are positioned to provide significant incremental coverage over current standards of care.

• Manufacturing agreements with Lonza and Thermo Fisher ensure capacity for global supply.